People on dialysis often face serious heart risks. A new analysis looked at two common heart medicines called spironolactone and eplerenone. These drugs block a specific receptor in the body to help manage fluid and pressure. The study combined data from 4,525 adults who were already on maintenance dialysis.
The results showed a clear benefit for heart health. Patients taking these medicines had significantly fewer nonfatal cardiovascular events. This means fewer heart attacks or strokes that did not immediately lead to death. The reduction was strong enough to be considered real and important for patient care.
However, the study also found serious safety concerns. There was a significantly higher risk of severe hyperkalemia, which is a dangerous buildup of potassium in the blood. Men taking these drugs also faced a much higher risk of gynecomastia and breast pain. These side effects can be severe and may require stopping the medication.
Clinicians must balance the heart benefits against these specific risks. The evidence suggests these drugs can help prevent heart trouble, but doctors need to watch potassium levels closely. They must also discuss the potential for breast pain and swelling with male patients before starting treatment.
